Elanco Animal Health Incorporated (ELAN) shares rallied 6.2% in the last trading session to close at $15.45. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.9% gain over the past four weeks.Elanco Animal Health Incorporated recorded a strong price increase after it announced Lawrence E. Kurzius as its next Chairman of the Board, effective at the conclusion of the company's 2024 Annual Meeting of Shareholde ...

Lawrence Kurzius to become next Chairman of the Board GREENFIELD, Ind., Jan. 2, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has named Lawrence E. Kurzius as its next Chairman of the Board, effective at the conclusion of the Company's 2024 Annual Meeting of Shareholders.  Mr. Kurzius, a member of the Elanco Board since 2018, will succeed current Chairman, R. David Hoover, who will remain on the Board as an independent director. "It has been ...

Business: Elanco is an animal health company that delivers products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species and offers products in two categories: Pet Health, which is focused on parasiticides, vaccines and therapeutics; and Farm Animal, which consists of products designed to prevent, control and treat health challenges primarily focused on cattle.Activist Commentary: Ancora is not an activist investor. It is primarily a family ...

Financial Data and Key Metrics Changes - The company reported a revenue of $1.068 billion, representing a 4% reported growth or 5% in constant currency, with foreign exchange rates presenting a headwind of $5 million compared to the third quarter of 2022 [77][34] - Adjusted EBITDA was $214 million, an increase of 5% compared to the third quarter of 2022, while adjusted EPS was $0.18, reflecting a 6% increase [51][34] - The company raised the midpoint of its constant currency revenue growth guidance, now expecting flat to 1% growth for the year, along with increased guidance for adjusted EBITDA and adjusted EPS despite increasing FX headwinds [24][86] Business Line Data and Key Metrics Changes - Total Pet Health revenue grew 6% in the third quarter, driven by price growth of 4%, while U.S. Pet Health revenue was flat due to competitive pressures [47][64] - International Pet Health experienced a 16% constant currency revenue growth, attributed to a better economic environment in Europe and expanded commercial capabilities [36][78] - Farm Animal revenue grew 4% in constant currency, with U.S. Farm Animal revenue increasing by 2%, primarily driven by innovation [79][66] Market Data and Key Metrics Changes - The company noted that only about 18% of its total global business is sold to U.S. vet clinics, indicating limited sensitivity to vet visit trends [35] - The international Farm Animal segment saw a 5% constant currency revenue growth, driven by strong underlying markets in cattle and poultry [26][79] - The OTC market for retail channels grew by 10% year-to-date, highlighting resilience in the market [25][34] Company Strategy and Development Direction - The company is focusing on a differentiated global omnichannel approach, leveraging its diverse portfolio and enhancing capabilities to drive topline growth [23][89] - There is a strong emphasis on innovation, with three late-stage potential blockbuster products expected to contribute to growth in 2024 [39][114] - The company is expanding its U.S. Pet Health sales team by 25% to deepen relationships with veterinary clinics and enhance market penetration [70][96] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage competitive pressures and macroeconomic headwinds, emphasizing a resilient market for pet health products [8][11] - The company anticipates continued price growth and stabilization of core volumes, supported by its omnichannel strategy [89][88] - Management highlighted the importance of innovation and customer focus as key drivers for sustainable growth moving forward [13][14] Other Important Information - The company has nearly completed the cash outlay necessary for project costs related to systems integration, expecting improved operating cash flow next year [27][84] - Interest expense was reported at $72 million, an increase of $14 million year-over-year due to higher interest rates, but the company has 76% of its debt fixed [51][10] - The company recorded a non-cash pretax goodwill impairment charge impacting reported EPS by $2.10, which was excluded from non-GAAP measures [54][86] Q&A Session Summary Question: What is the most important uncertainty or risk factor for 2024? - Management identified competition, regulatory challenges, and macroeconomic headwinds as key uncertainties for 2024 [8][17] Question: Can you elaborate on the trends in the retail business? - Management noted that the OTC business is growing, with a focus on expanding physical availability in various retail channels [105][104] Question: How is the company preparing for multiple product launches? - The company is ramping up its sales force and establishing relationships with clinics to ensure readiness for upcoming product launches [142][128] Question: What are the expectations for revenue growth in 2024? - Management committed to constant currency revenue growth for 2024, excluding contributions from potential blockbuster products [127][122]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 incorporation or organization) Identification No.) INDIANA 82-5497352 2500 INNOVATION WAY, GREENFIELD, INDIANA ...

Financial Data and Key Metrics Changes - The company reported revenue of $1.057 billion for Q2 2023, a decline of 10% or 9% in constant currency, with price contributing 4% to the quarter's performance [51][56] - Adjusted EBITDA was $222 million, reflecting a decline of 27%, with an estimated headwind from the ERP blackout impacting results [56] - The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, now expecting revenue between $4.35 billion and $4.41 billion [85][73] Business Line Data and Key Metrics Changes - U.S. Pet Health returned to growth with a 1% increase year-over-year, driven by strong performance in the OTC retail market and new product launches [29][41] - International Pet Health declined 7% in constant currency, primarily due to demand pressure in the Spain retail market, but the European launch of Adtab exceeded expectations [41][67] - The International Farm Animal business grew 4% in constant currency, driven by strength in poultry and aqua, while the U.S. Farm Animal business declined 5% due to supply disruptions [42][53] Market Data and Key Metrics Changes - The U.S. Pet Health market saw a strong parasiticides season contributing to growth in both units and total sales, with Seresto and Advantage brands growing revenue in high-single digits [29][30] - The company noted a 36% increase in total touch points with veterinarians and clinics, contributing to stabilization in the U.S. vet market [30] - The company expects improvement in the International Pet Health business in the second half of 2023, leveraging innovation and a better economic environment in Europe [41] Company Strategy and Development Direction - The company is focused on increasing manufacturing capacity for its canine parvovirus monoclonal antibody by 10x, anticipating significant sales growth in 2024 [9][35] - The company is investing in its U.S. Pet Health business to maximize the potential of its portfolio, including new product launches and global market expansion [47][49] - The company aims to enhance its innovation pipeline, with several late-stage products expected to contribute significantly to revenue starting in 2024 [38][75] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to revenue growth in the second half of 2023, driven by new product ramps and improved supply for vaccines [86][89] - The company highlighted the importance of its late-stage pipeline and the expected differentiation of its products, which is critical for long-term success [75][92] - Management noted that the resolution of the EPA review for Seresto is a positive development, reaffirming the product's long-term growth potential [45][121] Other Important Information - The company completed its ERP integration, which is expected to provide synergies and improve operational efficiency [44][51] - The company ended the quarter with net debt of $5.75 billion and plans to retire $344 million of notes due in 2023 [59][60] - The company anticipates a year-end net leverage ratio between 5.5x and 5.8x, reflecting durable cash flows and a focus on debt paydown [60][84] Q&A Session Summary Question: Can you discuss the assumptions for the fast growth of parvo? - Management highlighted the strong start for the parvovirus product, with early efficacy reports showing quicker recovery times and higher success rates [6][9] Question: What are the new marketing strategies for Seresto and Advantage? - Management mentioned increased share of voice through campaigns and improved physical availability in stores, contributing to revenue growth [10][115] Question: Can you clarify the second half EBITDA bridge? - Management indicated that investments in the sales force and marketing for the U.S. Pet Health team are key components of the EBITDA bridge for the second half [80][81] Question: What is the long-term growth outlook for Seresto? - Management expressed confidence in Seresto's long-term growth, citing increased physical availability, innovation, and strong market demand [121] Question: What are the additional investments planned for next year? - Management noted that investments will focus on expanding the sales force and marketing efforts to support new product launches [103][104]

2023 Earnings – Second Quarter 2 Non-GAAP Financial Measures. This presentation contains non-GAAP financial measures, such as revenue excluding the impact of foreign exchange rate effects, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted EPS, adjusted gross profit, adjusted gross margin, net debt and net debt leverage, which we use to assess and analyze our operational results and trends. Reconciliation of non-GAAP financial measures and reported GAAP fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdictio ...

Elanco Animal Health Inc. (NYSE:ELAN) Q1 2023 Results Conference Call May 9, 2023 9:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Erin Wright - Morgan Stanley Balaji Prasad - Barclays Umer Raffat - Evercore ISI Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Group Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazqu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdicti ...